Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Embecta Corporation ( (EMBC) ) has released its Q4 earnings. Here is a breakdown of the information Embecta Corporation presented to its ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents ...

B, consensus $1.12B.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference ...

Embecta Corp. (NASDAQ: EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago.